Analysts are hoping that GlaxoSmithKline plc (ADR) (NYSE:GSK) can stabilize the company amid a series of new strategies that the CEO, Andrew Witty, has been implementing in recent months. Bernstein analyst Tim Anderson has reviewed the company that decided to let go of the cancer treatment drugs and focus instead on the vaccine groups. Anderson […]
Christopher Gent
Recent Stories
Oracle Corporation (NASDAQ:ORCL) Opens Second Oracle Cloud Infrastructure (OCI) Region In India
Will CBD Become Robinhood’s Next Focus? (YCBD, NEPT, MCTC, ACB, MJNA)
Macy’s Inc (NYSE:M) and J C Penney Company Inc (OTCMKTS:JCPNQ) To Consider Reinventing Their Business Operations
Intel Corp (NASDAQ:INTC) Acquires $253.5 Million Interest in Reliance Jio Platforms
How Pot Stocks Shape Up in H2 2020 (TLRY, LHSIF, NUGS, CURLF, APHA)